Trial Information
Summary: First Episode Psychosis Study (CAFÉ)
What is the purpose of this study?
The purpose of this study is to compare the effectiveness and side
effects of three antipsychotic medications (olanzapine, quetiapine,
and risperidone) for the treatment of schizophrenia,
schizophreniform, or schizoaffective disorder. All of these
medications are currently approved by the FDA for use in the United
States. We will study the main reasons why study participants stop
taking each of the study medications because this problem sometimes
is encountered in the treatment of your illness. We will also study
the effects of the medications on your symptoms and functioning. We
will study the side effects of the medications, your use of mental
health services, and your quality of life.
What will I have to do if I decide to participate in
this study?
You will participate in up to 24 scheduled study visits (an initial
visit to see if you qualify for the study, a baseline visit for
additional tests and the assignment of a study medication, visits
once a week for the first six weeks of treatment, once every other
week for the next six weeks, and then monthly visits for the rest
of the study). There are three phases to this study. In the first
phase, you will participate in an evaluation to determine if you
are eligible for the study. In the second phase, you will be
randomly assigned (like the flip of a coin) to one study medication
and do well, you may continue with the study medication up to four
more months by entering phase 3 of the study.
You (and your family members, if they can attend study visits)
will receive basic information about your illness, what you can
expect to happen in the course of your illness, how you can deal
with these changes, what you can expect from the study drug
treatment and what mental health services and support groups are
available to you locally.
You or your study doctor may decide to stop the study
medication and end your participation in the study at any
time.
What are the risks of participating in this
study?
There is a risk that your symptoms of your illness will not respond
to the study medication. Your symptoms may worsen if the study drug
is ineffective for you. You will be told if any new information is
learned which may affect your illness or influence your willingness
to continue participation in this study.
Will I be paid to participate in the
study?
You may receive up to $10 per visit for your participation in this
study to help offset the cost of transportation and your effort.
Payment will be made by check at the end of your study
participation.
|
Contact:
Rona Hu, M.D., Principle Investigator
Stanford University School of Medicine
401 Quarry Road
Stanford, CA
Telephone: 650-723-7041
Fax: 650-723-2507
Email:
|
|

If you would like to learn more about participating in this study, please send an e-mail message using the form below.
Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.
This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.
Trial listings updated: June 1, 2008 at 5:43:20 AM